|
Goldston K, Baillie AJ. Depression and coronary heart disease:A review of the epidemiological evidence, explanatory mechanisms and management approaches [J]. Clinical Psychology Review, 2008, (2):288.doi: 10.1016/j.cpr.2007.05.005.
|
|
Carney RM, Freedland KE, Veith RC. Major depression, heart rate and plasma norepinephrine in patients with coronary heart disease [J]. Biological Psychiatry, 1999.458.doi: 10.1016/S0006-3223(98)00049-3.
|
|
Stein PK, Carney RM, Freedland KE. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease [J]. Journal of Psychosomatic Research, 2000.493.doi: 10.1016/S0022-3999(99)00085-9.
|
|
Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease [J]. American Heart Journal, 2000.S57.doi: 10.1067/mhj.2000.109978.
|
|
Chrapko WE, Juracz P, Radomski MW. Decreased plasma nitric oxide metabolites and platelet nitric oxide synthase activity in patients with major depression [J]. Biological Psychiatry, 2004.129.doi: 10.1016/j.biopsych.2004.03.003.
|
|
Jarvisalo MJ, Harmoinen A, Hakanen M. Elevated serum C-reactive protein levels and early arterial changes in healthy children [J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002.1323.doi: 10.1161/01.ATV.0000024222.06463.21.
|
|
Musselman DL, Marzec UM, Manatunga A. Platelet reactivity in depressed patients treated with Paroxetine:Preliminary findings [J]. Archives of General Psychiatry, 2000, (9):872.doi: 10.1001/archpsyc.57.9.875.
|
|
Iosifescu DV, Clementi-Craven N, Fraguas R. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder [J]. Psychosomatic Medicine, 2005, (5):703.doi: 10.1097/01.psy.0000170338.75346.d0.
|
|
Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression [J]. American Journal of Psychiatry, 1997.497.
|
|
Paffenbarger RS Jr, Kampert JB, Lee IM. Changes in physical activity and other life way patterns influencing longevity [J]. Medicine and Science in Sports and Exercise, 1994(7):857.doi: 10.1249/00005768-199407000-00008.
|
|
Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction:Its nature and consequences [J]. Psychosomatic Medicine, 1996.99.
|
|
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for non-compliance with medical treatment:Meta-analysis of the effects of anxiety and depression on patient adherence [J]. Archives of Internal Medicine, 2000.2101.doi: 10.1001/archinte.160.14.2101.
|
|
Ziegelstein RC, Fauerbach JA, Stevens SS. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction [J]. Archives of Internal Medicine, 2000.1818.doi: 10.1001/archinte.160.12.1818.
|
|
Wang PS, Bohn RL, Knight E. Non-compliance with antihypertensive medications:The impact of depressive symptoms and psychosocial factors [J]. Journal of General Internal Medicine, 2002, (7):504.doi: 10.1046/j.1525-1497.2002.00406.x.
|
|
Horsten M, Wamala SP, Vingerhoets A. Depressive symptoms, social support and lipid profile in healthy middle-aged women [J]. Psychosomatic Medicine, 1997.521.
|
|
Lesperance F, Frasure-Smith N. Depression and heart disease [J]. Cleveland Clinic Journal of Medicine, 2007, (Suppl 1):S63.doi: 10.3949/ccjm.74.Suppl_1.S63.
|
|
Strawbridge WJ, Deleger S, Roberts RE. Physical activity reduces the risk of subsequent depression for older adults [J]. American Journal of Epidemiology, 2002(4):328.doi: 10.1093/aje/kwf047.
|
|
Lisanby SH, Morales O, Payne N. New developments in electroconvulsive therapy and magnetic seizure therapy [J]. CNS Spectrums, 2003.529.
|
|
Kim EJ, Kim WR, Chi SE. Repetitive transcranial magnetic stimulation protects hippocampal plasticity in an animal model of depression [J]. Neuroscience Letters, 2006, (1/2):79.doi: 10.1016/j.neulet.2006.06.023.
|
|
Sakkas P, Psarros C, Papadimitriou GN. Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction [J]. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2006, (5):960.doi: 10.1016/j.pnpbp.2006.01.023.
|
|
Summers KM, Martin KE, Watson K. Impact and Clinical Management of Depression in Patients with Coronary Artery Disease [J]. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy, 2010.304.
|
|
Somberg TC, Arora RR. Depression and Heart Disease:Therapeutic Implications [J]. Cardiology, 2008.75.doi: 10.1159/000119692.
|
|
Roose SP, Glassman AH, Attia E. Cardiovascular effects of fluoxetine in depressed patients with heart disease [J]. American Journal of Psychiatry, 1998.660.
|
|
Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction [J]. CIRCULATION, 2001, (16):1894.doi: 10.1161/hc4101.097519.
|
|
Amsterdam JD, Garcia-Espana F, Fawcett J. Blood pressure changes during short-term fluoxetine treatment [J]. Journal of Clinical Psychopharmacology, 1999, (1):9.doi: 10.1097/00004714-199902000-00004.
|
|
Wernicke J, Lledó A, Raskin J. An Evaluation of the Cardiovascular Safety Profile of Duloxetine Findings from 42 Placebo-Controlled Studies [J]. Drug Safety, 2007, (5):437.doi: 10.2165/00002018-200730050-00007.
|
|
Taylor D. Antidepressant drugs and cardiovascular pathology:a clinical overview of effectiveness and safety [J]. Acta Psychiatrica Scandinavica, 2008, (6):434.doi: 10.1111/j.1600-0447.2008.01260.x.
|
|
袁勇贵, 张心保. 新型抗抑郁药米氮平 [J]. 中国新药与临床杂志, 2001, (3):219.doi: 10.3969/j.issn.1007-7669.2001.03.026.
|
|
Vieweg WV, Julius DA, Fernandez A. Treatment of depression in patients with coronary heart disease [J]. American Journal of Medicine, 2006, (7):567.doi: 10.1016/j.amjmed.2006.02.037.
|
下载:
苏公网安备 32100302010246号
